Investor Presentation
Q2 FY21
Investor Presentation
Q4 FY20
Investor Presentation
Q4 FY18
Investor Presentation
Q3 FY18
Investor Presentation
Q2 FY18
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Bearish
4
Neutral
4
Bullish
6
Bearish
36
Neutral
4
Bullish
6
Bearish
32
Neutral
0
Bullish
0

Market Cap
₹ 47 Cr
P/E
94.30
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
47 Cr
Moderate Risk
94.3
30.8
2.2
0.8
31.40
8.21
Sales CAGR
1Y
-19.47%
3Y
-19.82%
5Y
-9.26%
10Y
—
Profit CAGR
1Y
43.73%
3Y
—
5Y
—
10Y
—
ROE
TTM
0.87%
3Y
-17.62%
5Y
-5.83%
10Y
—
ROCE
TTM
-11.71%
3Y
-15.84%
5Y
-2.40%
10Y
—
Performance
UNDER PERFORMER
Valuation
REASONABLE
Growth
SLUGGISH
Profitability
LOW MARGIN
Technicals
Bearish
Risk
HIGH RISK
Change in Directors/KMP
12 hours ago
Appointment of Company Secretary and Compliance Officer
Mrs. Mitti Jain has been appointed as the Company Secretary and Compliance Officer of Lasa Supergenerics Limited, effective December 16, 2025.
Change in Directors/KMP
4 days ago
Resignation of Whole-time Director
Mr. Prathmesh Chalke has resigned as Whole-time Director of the Company effective December 31, 2025.